Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus;Anti-CD20-therapie zur remissionsinduktion und -erhaltung bei therapierefraktärem systemischen lupus erythematodes

Zeitschrift fur Rheumatologie

Volumn 66, Issue 4, 2007, Pages 328-336

  Chehab, G ^a   Sander, O ^a   Fischer Betz, R ^a   Schneider, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anti CD20; B cell depletion; Case reports; Rituximab; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CHIMERIC PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ERYTHEMA; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; LEUKOPENIA; MALE; MORTALITY; MYELITIS; MYOCARDITIS; NEPHRITIS; NEUROLOGICAL COMPLICATION; REMISSION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 34447314441     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-007-0164-6     Document Type: Article

References (21)

1. Bencivelli W, Vitali C, Isenberg DA et al. (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10: 549-554
2. Braendstrup P, Bjerrum OW, Nielsen OJ et al. (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78: 275-280
3. Chan O, Shlomchik MJ (1998) A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 160: 51-59
4. Chan OT, Hannum LG, Haberman AM et al. (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189: 1639-1648
5. Cohen AS, Canoso JJ (1972) Criteria for the classification of systemic lupus erythematosus-status 1972. Arthritis Rheum 15: 540-543
6. Cooper N, Stasi R, Cunningham-Rundles S et al. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125: 232-239
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390-1400
8. Gottenberg JE, Guillevin L, Lambotte O et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920
9. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725-1734
10. Leandro MJ, Cambridge G, Edwards JC et al. (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545
11. Leandro MJ, Edwards JC, Cambridge G et al. (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673-2677
12. Looney RJ, Anolik JH, Campbell D et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589
13. Ng KP, Leandro MJ, Edwards JC et al. (2006) Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 65: 942-945
14. Penalver FJ, Jimenez-Yuste V, Almagro M et al. (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 86: 400-404
15. Sfikakis PP, Boletis JN, Lionaki S et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52: 501-513
16. Shlomchik MJ, Madaio MP, Ni D et al. (1994) The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 180: 1295-1306
17. Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277
18. Tokunaga M, Fujii K, Saito K et al. (2005) Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44: 176-182
19. Vitali C, Bencivelli W, Isenberg DA et al. (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10: 527-539
20. Vitali C, Bencivelli W, Isenberg DA et al. (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10: 541-547
21. Winkler U, Jensen M, Manzke O et al. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224